Cardiovascular and HIV Drug Interactions

  • John J. FaragonEmail author
  • Nimish Patel


Drug interactions with HIV medications are complex. When managing concurrent cardiovascular disease, statins, antiplatelets, anticoagulants, and antihypertensives are among select classes that are likely to lead to significant interactions. The greatest risk of drug interactions is associated with the use of cobicistat- or ritonavir-boosted HIV regimens. The lowest risk of drug interactions is associated with the use of raltegravir, dolutegravir, bictegravir, or rilpivirine-containing regimens. Providers are encouraged to use online databases for drug interaction screening when changing a medication used in managing cardiovascular disease or when altering any HIV regimen.


Drug interactions Cardiovascular disease HIV Statins Antiplatelets Anticoagulants Antihypertensives 


  1. 1.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 25, 2018. Available at: Accessed 10 Jan 2019.
  2. 2.
    Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320(4):379–96Google Scholar
  3. 3.
    Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001;34(13):984–96.CrossRefGoogle Scholar
  4. 4.
    Hansten PD. Drug interactions. In: Koda-Kimble MA, editor. Applied therapeutics: the clinical use of drugs. Vancouver: Applied Therapeutics, Inc.; 1995. p. 1–3.Google Scholar
  5. 5.
    ILO B. Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action, and elimination. In: Brunton LL, editor. Goodman and Gilman’s the pharmacologic basis of therapeutics. 11th ed. New York: McGraw Hill; 2005. p. 1–40.Google Scholar
  6. 6.
    Tivicay [package insert]. Research Triangle Park: ViiV Healthcare; 2016.Google Scholar
  7. 7.
    Isentress [package insert]. Whitehouse Station: Merck; 2016.Google Scholar
  8. 8.
    Norvir [package insert]. North Chicago: AbbVie; 2016.Google Scholar
  9. 9.
    Genvoya [package insert]. Foster City: Gilead; 2017.Google Scholar
  10. 10.
    Sustiva [package insert]. Princeton: Bristol-Myers Squib; 2017.Google Scholar
  11. 11.
    Viramune XR [package insert]. Ridgefield: Boehringer Ingelheim; 2017.Google Scholar
  12. 12.
    Edurant [package insert]. Titusville: Janssen; 2015.Google Scholar
  13. 13.
    Intellence [package insert]. Titusville: Janssen; 2014.Google Scholar
  14. 14.
    Pradaxa [package insert]. Ridgefield: Boehringer Ingelheim; 2015.Google Scholar
  15. 15.
    Apixiban [package insert]. Princeton: Bristol-Myers Squib; 2016.Google Scholar
  16. 16.
    Xarelto [package insert]. Titusville: Janssen; 2016.Google Scholar
  17. 17.
    Savaysa [package insert]. Parsippany: Daiichi Sankyo; 2015.Google Scholar
  18. 18.
    Kwong LM, Tong LM. Drug interactions with rivaroxaban following total joint replacement surgery. Ann Pharmacother. 2012;46:1232–8.CrossRefGoogle Scholar
  19. 19.
    Bates D, Dalton B, Gilmour J. Venous thromboembolism due to suspected interaction between rivaroxaban and nevirapine. Can J Hosp Pharm. 2013;66:125–9.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Perram J, Joseph J, Holloway C. Novel oral anticoagulants and HIV: dabigatran use with Antiretrovirals. BMJ Case Rep. 2015;20. PUBMED ID 26590187.
  21. 21.
    Egan G, Hughes CA, Ackman ML. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother. 2014;48(6):734–40.CrossRefGoogle Scholar
  22. 22.
    Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.CrossRefGoogle Scholar
  23. 23.
    O’Gara PT, Kushner FG, Ascheim DD. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78–e140.CrossRefGoogle Scholar
  24. 24.
    Brillinta [package insert]. Wilmington: AstraZeneca; 2016.Google Scholar
  25. 25.
    Plavix [package insert]. Princeton: Bristol-Myers Squib; 2016.Google Scholar
  26. 26.
    Effient [package insert]. Indianapolis: Eli Lill; 2015.Google Scholar
  27. 27.
    Farid NA, Jakubowski JA, Payne CD. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Curr Med Res Opin. 2009;25:1821–9.CrossRefGoogle Scholar
  28. 28.
    Ancrenaz V, Déglon J, Samer C, Staub C, Dayer P, Daali Y, et al. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin Pharmacol Toxicol. 2013;112(2):132–7.CrossRefGoogle Scholar
  29. 29.
    Sharma GK, Megaly M. Etravirine as a culprit in recurrent drug-eluting in-stent restenosis in an HIV patient. Int J Cardiol. 2016;219:117–8.CrossRefGoogle Scholar
  30. 30.
    Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011;50(1):25–39.CrossRefGoogle Scholar
  31. 31.
    Marsousi N, Samer CF, Fontana P, Reny JL, Rudaz S, Desmeules JA, et al. Coadministration of ticagrelor and ritonavir: toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clin Pharmacol Ther. 2016;100(3):295–304.CrossRefGoogle Scholar
  32. 32.
    Stone NJ, Robinson J, Lichtenstein AH, Bairey MCN, Blum CB, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;129:S1–S45.Google Scholar
  33. 33.
    Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV medical association of the infectious diseases society of America and the adult AIDS clinical trials group. Clin Infect Dis. 2003;37:613–27.CrossRefGoogle Scholar
  34. 34.
    Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med. 2007;20(4):411–6.CrossRefGoogle Scholar
  35. 35.
    Cheng CH, Miller C, Lowe C, Pearson VE. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm. 2002;59(8):728–30.CrossRefGoogle Scholar
  36. 36.
    Aboulafia DM, Johnston R. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Patient Care STDs. 2000;14(1):13–8.CrossRefGoogle Scholar
  37. 37.
    Hare CB, Vu MP, Grunfeld C, Lampiris HW. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis. 2002;35(10):e111–2.CrossRefGoogle Scholar
  38. 38.
    Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: AIDS clinical trials group (ACTG) study A5047. AIDS. 2002;16:569–77.CrossRefGoogle Scholar
  39. 39.
    Hulgan T, Sterling TR, Daugherty J, Arbogast PG, Raffanti S, Ray W. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. JAIDS. 2005;38(3):277–82.PubMedGoogle Scholar
  40. 40.
    Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS clinical trials group 5108 study. JAIDS. 2005;39:307–12.PubMedGoogle Scholar
  41. 41.
    Mikhail N, Iskander E, Cope D. Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin. Curr Drug Saf. 2009;4(2):121–2.CrossRefGoogle Scholar
  42. 42.
    Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS clinical trials group study 5087. AIDS Res Hum Retrovir. 2005;21:757–67.CrossRefGoogle Scholar
  43. 43.
    Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 2001;45(12):3445–50.CrossRefGoogle Scholar
  44. 44.
    Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDs. 2003;17(5):207–10.CrossRefGoogle Scholar
  45. 45.
    Castro JG, Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am J Med. 2002;112(6):505.CrossRefGoogle Scholar
  46. 46.
    Van der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther. 2007;12:1127–32.PubMedGoogle Scholar
  47. 47.
    Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. JAIDS. 2008;47(5):570–8.PubMedGoogle Scholar
  48. 48.
    Busti AJ, Bain AM, Hall RG, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008;51(6):605–10.CrossRefGoogle Scholar
  49. 49.
    Yu CY, Campbell SE, Sponseller CA, et al. Steady-state pharmacokinetic interactions of darunavir/ritonavir with pitavastatin in healthy adult volunteers. In: Program and abstracts of the XIX International AIDS Conference, July 22–27, 2012; Washington, DC. Abstract TUPE053.Google Scholar
  50. 50.
    Sponseller C, et al. Pitavastatin 4 mg provides greater low-density lipoprotein cholesterol reduction compared to pravastatin 40 mg over 12 weeks of treatment in HIV+ adults with dyslipidemia 20th conference on retroviruses and opportunistic infections. Atlanta Georgia, March 3–6. Abstract 187LB.Google Scholar
  51. 51.
    Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidemia (INTREPID): 12 week and 52 week results of a phase 4, multicenter, randomized, double blind, superiority trial. Lancet HIV. 2017;4(4)
  52. 52.
    Evaluating the use of pitavastatin to reduce the risk of cardiovascular disease in HIV-infected adults (REPRIEVE). Located at
  53. 53.
    Busse KH, Hadigan C, Chairez C, et al. Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. JAIDS. 2009;52:235–9.PubMedGoogle Scholar
  54. 54.
    Reyataz [package insert]. Princeton: Bristol-Myers Squib; 2016.Google Scholar
  55. 55.
    Baeza MT, Merino E, Boix V, Vliment E. Nifedipine-lopinavir/ritonavir severe interaction: a case report. AIDS. 2007;21(1):119–20.CrossRefGoogle Scholar
  56. 56.
    Rossi DR, Rathburn RC, Slater LN. Symptomatic orthostasis with extended-release nifedipine and protease inhibitors. Pharmacotherapy. 2002;22(10):1312–6.CrossRefGoogle Scholar
  57. 57.
    Naccarato M, Yoong D, la Porte C, Fong I. Amiodarone and concurrent antiretroviral therapy: a case report and review of the literature. Antivir Ther. 2014;19(4):329–39.CrossRefGoogle Scholar
  58. 58.
    Invirase [package insert]. South San Francisco: Genentech; 2015.Google Scholar
  59. 59.
    Aptivus [package insert]. Ridgefield: Boehringer Ingelheim; 2016.Google Scholar
  60. 60.
    Tikosyn [package insert]. New York: Pfizer; 2016.Google Scholar
  61. 61.
    Biktarvy [package insert]. Foster City:Gilead; 2018.Google Scholar
  62. 62.
    Schmitt C, Kaeser B, Riek M, Bech N, Kreuzer C. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. Int J Clin Pharmacol Ther. 2010;48(3):192–9.Google Scholar
  63. 63.
    Hunt K, Hughes CA, Hills-Nieminen C. Protease inhibitor-associated QT interval prolongation. Ann Pharmacother. 2011;45(12):1544–50.Google Scholar
  64. 64.
    Drew BJ, et al. Prevention of torsades de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55(9):934–47.Google Scholar
  65. 65.
    QTDrugs Lists. Located at Accessed 5 May 2017.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of PharmacyAlbany Medical Center HospitalAlbanyUSA
  2. 2.Skaggs School of Pharmacy and Pharmaceutical SciencesUniversity of California at San DiegoSan DiegoUSA

Personalised recommendations